# US 2008/0075737 A1 · Adeno-Associated Virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075737 A1
- Document ID: US20080075737A1
- Status: Published application
- Kind: A1
- Application number: 11/899,500
- Filed: 2007-09-06
- Published: 2008-03-27
- Earliest claimed: 2001-12-17
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: Guangping Gao; James Wilson; Mauricio Alvira
- Web page: https://patentgrep.com/patent/US20080075737A1

## CPC

- C12N 15/86: Viral vectors
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/761: Adenovirus
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/45: Transferases (2)
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/20: for DNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/005: from viruses
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/755: Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/1018: {Carboxy- and carbamoyl transferases (2.1.3)}
- C12N 9/644: {Coagulation factor IXa (3.4.21.22)}
- C12N 15/8645: {Adeno-associated virus}
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- C12Y 304/21022: Coagulation factor IXa (3.4.21.22)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/85: mammalian
- C12Y 201/03003: Ornithine carbamoyltransferase (2.1.3.3)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. rAAV8-mediated delivery of therapeutic and immunogenic genes, including Factor VIII, is also provided.

## Claims

### Claim 1

A method of inducing an immune response to an HIV antigen, said method comprising delivering an adeno-associated virus (AAV) vector comprising an AAV8 capsid protein having an amino acid sequence of amino acids 1 to 737 of SEQ ID NO:2 or a sequence which is at least 95% identical therewith,
and a transgene encoding a product under control of regulatory elements that direct expression of the product to a subject, wherein said product is selected from the group consisting of HIV antigens and simian immune deficiency antigens.

### Claim 2 (depends on 1)

The method according to claim 1 wherein said viral vector is formulated for intramuscular delivery.

### Claim 3

An immunogenic regimen comprising delivery of an adeno-associated virus (AAV) vector comprising an AAV8 capsid protein having an amino acid sequence of amino acids 1 to 737 of SEQ ID NO:2 or a sequence which is at least 95% identical therewith,
and a transgene encoding a product under control of regulatory elements that direct expression of the product in a host cell, wherein said product is an immunogen.

### Claim 4 (depends on 3)

The immunogenic regimen according to claim 3, wherein said immunogen is selected from the group consisting of HIV and simian immune deficiency antigens.

### Claim 5 (depends on 3)

The immunogenic regimen according to claim 3, wherein said viral vector is formulated for intramuscular delivery.

### Claim 6

A host cell containing a molecule comprising an adeno-associated 8 (AAV8) nucleic acid capsid sequence selected from the group consisting of:
vp1, nt 2121 to 4335;
vp2, nt 2532 to 4335; and
vp3, nt 2730 to 4335, wherein the nucleotides numbers are of AAV8, SEQ ID NO:1
and a heterologous nucleic acid sequence comprising a functional AAV rep protein

### Claim 7 (depends on 6)

The host cell according to claim 6, wherein the functional AAV rep gene is from an AAV selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6.

### Claim 8 (depends on 6)

The host cell according to claim 6, wherein said nucleic acid sequence further comprises a sequence selected from the group consisting of: nucleic acids 905 to 2104 of SEQ ID NO:1; nucleic acids 237 to 2104 of SEQ ID NO:1; nucleic acids 905 to 2104 of SEQ ID NO:1; and nucleic acids 237 to 2104 of SEQ ID NO:1

### Claim 9 (depends on 6)

The molecule according to claim 6, wherein said molecule is a plasmid.

### Claim 10 (depends on 7)

A method of generating a recombinant adeno-associated virus (AAV) comprising an AAV8 capsid comprising the steps of culturing a host cell according to claim 7, said host cell containing: (a) a molecule encoding an AAV capsid protein; (b) a functional rep gene; (c) a minigene comprising AAV inverted terminal repeats (ITRs) and a transgene; and (d) sufficient helper functions to permit packaging of the minigene into the AAV capsid protein.

### Claim 11

An adeno-associated virus capsid protein comprising one or more fragments of an AAV8 capsid protein fused to a heterologous protein, wherein said one or more fragments of an AAV8 capsid protein are selected from the group consisting of:
a fragment of an AAV8 encompassing hypervariable region (HVR)1 through 12 selected the group consisting of: aa 146 to 152; aa 182 to 187; aa 262 to 264; aa 263 to 266; aa 381 to 383; aa 383 to 385; aa 450 to 474; aa 451 to 475; aa 490 to 495; aa 491 to 496; aa500 to 504; aa 501 to 505; aa 514 to 522; aa 533 to 554; aa 534 to 555; aa 581 to 594; aa 583 to 596; aa 658 to 667; aa 660 to 669; aa 705 to 719; aa 707 to 723;
aa 24 to 42, aa 25 to 28; aa 81 to 85; aa 133 to 165; aa 134 to 165; aa 137 to 143; aa 154 to 156; aa 194 to 208; aa 261 to 274; aa 262 to 274; aa 171 to 173; aa 185 to 198; aa 413 to 417; aa 449 to 478; aa 494 to 525; aa 534 to 571; aa 581 to 601; aa 660 to 671; aa 709 to 723; and
aa 1 to 184, aa 199 to 259; aa 274 to 446; aa 603 to 659; aa 670 to 706; aa 724 to 736; aa 185 to 198; aa 260 to 273; aa447 to 477; aa495 to 602; aa603 to 659; aa 660 to 669; and aa707 to 723, wherein the amino acid numbers are those of the AAV2 capsid, SEQ ID NO:4 and corresponding regions in the capsid of AAV8, SEQ ID NO:2.

### Claim 12 (depends on 11)

A composition comprising a protein according to claim 11 and a physiologically compatible carrier.

### Claim 13 (depends on 11)

A recombinant adeno-associated virus (AAV) comprising a capsid according to claim 11.

### Claim 14 (depends on 13)

A composition comprising an AAV according to claim 13 and a physiologically compatible carrier.

### Claim 15 (depends on 13)

A method of delivering a transgene to a cell, said method comprising the step of contacting the cell with an rAAV according to claim 13, wherein said rAAV comprises the transgene.

### Claim 16 (depends on 11)

A nucleic acid sequence encoding a protein according to claim 11.

### Claim 17

An isolated AAV8 nucleic acid sequence selected from the group consisting of:
vp1, nt 2121 to 4335;
vp2, nt 2532 to 4335; and
vp 3, nt 2730 to 4335,
wherein the nucleotides numbers are of AAV8, SEQ ID NO:1.

### Claim 18

An isolated nucleic acid molecule encoding adeno-associated virus 8 (AAV8), said molecule having the nucleic acid sequence of SEQ ID NO: 1 or a sequence which is at least 95% identical therewith.
